Compare SELF & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | PSTV |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 46.4M |
| IPO Year | 1997 | 2016 |
| Metric | SELF | PSTV |
|---|---|---|
| Price | $5.08 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 23.9K | ★ 3.9M |
| Earning Date | 05-08-2026 | 03-12-2026 |
| Dividend Yield | ★ 5.71% | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $12,530,280.00 | $5,213,000.00 |
| Revenue This Year | $1.59 | $21.93 |
| Revenue Next Year | $1.62 | $279.39 |
| P/E Ratio | $33.80 | ★ N/A |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $4.73 | $0.16 |
| 52 Week High | $5.83 | $1.77 |
| Indicator | SELF | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 36.53 |
| Support Level | $5.03 | $0.21 |
| Resistance Level | $5.22 | $0.32 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 42.11 | 7.86 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).